Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7271" target="_blank" >RIV/00064203:_____/11:7271 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:7271 RIV/00216208:11120/11:00003577

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pubmed/21822931" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/21822931</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1

Popis výsledku v původním jazyce

The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2. Variants in GCG may associate with type 2 diabetes, obesity and/or related metabolic traits. GCG was re-sequenced as a candidate gene in 865 European individuals. Twenty-nine variants were identified. Four variants that were considered to have a likelihood for altered functionality: rs4664447, rs7581952, Ile158Val and Trp169Ter, were genotyped in 17,584 Danes. When examined in 5,760 treatment-naive individuals, homozygous carriers of the low frequency (minor allele frequency 2.3%) G allele of rs4664447, predicted to disrupt an essential splice enhancer binding site, had lower levels of fasting plasma glucose (mean +/- SD, 4.8 +/- 1.2 vs 5.5 +/- 0.8 mmol/l, p = 0.004); fasting serum insulin (22 +/- 14 vs 42 +/- 27 pmol/l, p = 0.04); glucose-stimulated serum insulin (159 +/- 83 vs 290 +/- 183 pmol/l, p = 0.01) and adult height (165 +/- 10 vs

Název v anglickém jazyce

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1

Popis výsledku anglicky

The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2. Variants in GCG may associate with type 2 diabetes, obesity and/or related metabolic traits. GCG was re-sequenced as a candidate gene in 865 European individuals. Twenty-nine variants were identified. Four variants that were considered to have a likelihood for altered functionality: rs4664447, rs7581952, Ile158Val and Trp169Ter, were genotyped in 17,584 Danes. When examined in 5,760 treatment-naive individuals, homozygous carriers of the low frequency (minor allele frequency 2.3%) G allele of rs4664447, predicted to disrupt an essential splice enhancer binding site, had lower levels of fasting plasma glucose (mean +/- SD, 4.8 +/- 1.2 vs 5.5 +/- 0.8 mmol/l, p = 0.004); fasting serum insulin (22 +/- 14 vs 42 +/- 27 pmol/l, p = 0.04); glucose-stimulated serum insulin (159 +/- 83 vs 290 +/- 183 pmol/l, p = 0.01) and adult height (165 +/- 10 vs

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetologia

ISSN

0012-186X

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

12

Strana od-do

2820-2831

Kód UT WoS článku

000295679800011

EID výsledku v databázi Scopus

—